Comparative Study Of Efficacy And Safety Of Omnic Ocas And Doxazosin


M.I. Davidov

Comparative study of efficacy and safety of Omnic OCAS and doxazosin
It includes the results of the comparison study of efficiency and safety of Omnic Okas (tamsulosin) and doxazosin in the treatment of benign prostatic hyperplasia (BPH). The open 12-weeks trial included 62 patients with BPH. The positive results of Omnic Okas treatment were achieved in 96,7% of patients. The symptom index IPSS decreased on 53%, nocturia in 4,9 times, quality of life increased in 2,1 times, maximal urinary flow rate – on 55%, the residual urine decreased on 70%, adverse effects revealed in 3,3% patients. Positive effect was achieved in 71,9% and safety in 75,0%. Doxazosin have no advantages compared with Omnic Okas. The frequency of adverse effects was in 3,1-18,8%. Doxazosin decreased systolic and diastolic blood pressure on 19 and 9 hg mm, myocardial ischemia – in 15,6%, and arrhythmias – in 12,5% patients, positive orthostatic test was registered in 37,5% of patients. Omnic Okas was more effective and safe drug for treating symptoms of BPH.

Similar Articles


Бионика Медиа